PLT012
Solid Tumors (HCC, Intrahepatic Bile Duct Cancer)
Phase 1Active
Key Facts
Indication
Solid Tumors (HCC, Intrahepatic Bile Duct Cancer)
Phase
Phase 1
Status
Active
Company
About Pilatus Biosciences
Pilatus Biosciences is a private, preclinical-stage biotech leveraging immunometabolism to develop novel cancer therapies. Its lead asset, PLT012, an anti-CD36 metabolic checkpoint antibody, has secured FDA Orphan Drug and Fast Track designations for hepatocellular carcinoma and is advancing into Phase 1 trials. The company, spun out from research at the Ludwig Institute for Cancer Research and University of Lausanne, is actively seeking partnerships and investment to advance its pipeline.
View full company profile